MET and head and neck squamous cell carcinoma: Studies focusing on c-MET inhibition has reported EGFR sensitivity towards erlotinib drug as well as erlotinib sensitization in a dominant-active c-Src subset of EGFR overexpressing HNSCC lines [94].